Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 276969, 7 pages
http://dx.doi.org/10.1155/2015/276969
Research Article

Effects of Antitumor Necrosis Factor Therapy on Osteoprotegerin, Neopterin, and sRANKL Concentrations in Patients with Rheumatoid Arthritis

1Department of Internal Medicine VI, Innsbruck Medical University, 6020 Innsbruck, Austria
2Division of Biological Chemistry, Biocenter, Innsbruck Medical University, 6020 Innsbruck, Austria

Received 28 June 2015; Revised 25 September 2015; Accepted 27 September 2015

Academic Editor: Giuseppe Murdaca

Copyright © 2015 Katharina Kurz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Rheumatoid arthritis is a systemic autoimmune disease characterized by joint erosions, progressive focal bone loss, and chronic inflammation. Methods. 20 female patients with moderate-to-severe rheumatoid arthritis were treated with anti-TNF-antibody adalimumab in addition to concomitant antirheumatic therapies. Patients were assessed for overall disease activity using the DAS28 score, and neopterin, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) concentrations as well as osteoprotegerin (OPG) and soluble receptor activator of NF-κB ligand (sRANKL) concentrations were determined before therapy and at week 12. Neopterin as well as OPG and sRANKL were determined by commercial ELISAs. Results. Before anti-TNF therapy patients presented with high disease activity and elevated concentrations of circulating inflammatory markers. OPG concentrations correlated with neopterin (, ), but not with DAS28. OPG concentrations and disease activity scores declined during anti-TNF-treatment (both ). Patients who achieved remission () or showed a good response according to EULAR criteria () presented with initially higher baseline OPG levels, which subsequently decreased significantly during treatment ( for remission, for good response). Conclusions. Adalimumab therapy was effective in modifying disease activity and reducing proinflammatory and bone remodelling cascades.